APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endometriosis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Endometriosis Treatment Market Outlook and Growth Opportunities 2026

21 December 2025191 pages

Choose your research edition.

Industry ResearchEndometriosis Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Endometriosis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Endometriosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endometriosis Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Endometriosis Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Endometriosis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Endometriosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Endometriosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Endometriosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Endometriosis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Endometriosis Treatment market include Bayer, Abbott, Ferring, Xianju Pharma, AstraZeneca, Merck & Co, Takeda Pharmaceutical, Theramex and Livzon Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Endometriosis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Endometriosis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Endometriosis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Endometriosis Treatment market.

Endometriosis Treatment Segment by Company

Bayer

Abbott

Ferring

Xianju Pharma

AstraZeneca

Merck & Co

Takeda Pharmaceutical

Theramex

Livzon Pharmaceutical Group

Beijing Biote Pharmaceutical Co., ltd

Endometriosis Treatment Segment by Type

Hormonal Contraceptives

Progesterone Replacement Therapy

GnRHAnalogue

Endometriosis Treatment Segment by Distribution Channel

Hospital

Retail Pharmacy

Others

Endometriosis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Endometriosis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Endometriosis Treatment key companies, revenue, market share, and recent developments.

3. To split the Endometriosis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Endometriosis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Endometriosis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Endometriosis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endometriosis Treatment industry.

Chapter 3: Detailed analysis of Endometriosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Endometriosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Endometriosis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Endometriosis Treatment Industry Trends Table 2. Endometriosis Treatment Industry Drivers Table 3. Endometriosis Treatment Industry Opportunities and Challenges Table 4. Endometriosis Treatment Industry Restraints Table 5. Global Endometriosis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Endometriosis Treatment Revenue Share by Company (2021-2026) Table 7. Global Endometriosis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Endometriosis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Endometriosis Treatment Company, Product Type & Application Table 10. Global Endometriosis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Endometriosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hormonal Contraceptives Table 15. Significant Companies of Progesterone Replacement Therapy Table 16. Significant Companies of GnRHAnalogue Table 17. Global Endometriosis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Endometriosis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Endometriosis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Endometriosis Treatment Sales Value Share by Type (2021-2026) Table 21. Global Endometriosis Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Others Table 25. Global Endometriosis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Endometriosis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Endometriosis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Endometriosis Treatment Sales Value Share by Application (2021-2026) Table 29. Global Endometriosis Treatment Sales Value Share by Application (2027-2032) Table 30. Global Endometriosis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Endometriosis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Endometriosis Treatment Sales Value Share by Region (2021-2026) Table 33. Global Endometriosis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Endometriosis Treatment Sales Value Share by Region (2027-2032) Table 35. Global Endometriosis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Endometriosis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Endometriosis Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Endometriosis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Endometriosis Treatment Sales Value Market Share by Country (2027-2032) Table 40. Bayer Company Information Table 41. Bayer Business Overview Table 42. Bayer Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bayer Endometriosis Treatment Product Portfolio Table 44. Bayer Recent Development Table 45. Abbott Company Information Table 46. Abbott Business Overview Table 47. Abbott Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Abbott Endometriosis Treatment Product Portfolio Table 49. Abbott Recent Development Table 50. Ferring Company Information Table 51. Ferring Business Overview Table 52. Ferring Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Ferring Endometriosis Treatment Product Portfolio Table 54. Ferring Recent Development Table 55. Xianju Pharma Company Information Table 56. Xianju Pharma Business Overview Table 57. Xianju Pharma Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Xianju Pharma Endometriosis Treatment Product Portfolio Table 59. Xianju Pharma Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AstraZeneca Endometriosis Treatment Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Merck & Co Company Information Table 66. Merck & Co Business Overview Table 67. Merck & Co Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck & Co Endometriosis Treatment Product Portfolio Table 69. Merck & Co Recent Development Table 70. Takeda Pharmaceutical Company Information Table 71. Takeda Pharmaceutical Business Overview Table 72. Takeda Pharmaceutical Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceutical Endometriosis Treatment Product Portfolio Table 74. Takeda Pharmaceutical Recent Development Table 75. Theramex Company Information Table 76. Theramex Business Overview Table 77. Theramex Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Theramex Endometriosis Treatment Product Portfolio Table 79. Theramex Recent Development Table 80. Livzon Pharmaceutical Group Company Information Table 81. Livzon Pharmaceutical Group Business Overview Table 82. Livzon Pharmaceutical Group Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Livzon Pharmaceutical Group Endometriosis Treatment Product Portfolio Table 84. Livzon Pharmaceutical Group Recent Development Table 85. Beijing Biote Pharmaceutical Co., ltd Company Information Table 86. Beijing Biote Pharmaceutical Co., ltd Business Overview Table 87. Beijing Biote Pharmaceutical Co., ltd Endometriosis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Beijing Biote Pharmaceutical Co., ltd Endometriosis Treatment Product Portfolio Table 89. Beijing Biote Pharmaceutical Co., ltd Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Endometriosis Treatment Product Image Figure 2. Global Endometriosis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endometriosis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Endometriosis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hormonal Contraceptives Image Figure 8. Progesterone Replacement Therapy Image Figure 9. GnRHAnalogue Image Figure 10. Global Endometriosis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Endometriosis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Endometriosis Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Retail Pharmacy Image Figure 15. Others Image Figure 16. Global Endometriosis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Endometriosis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Endometriosis Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Endometriosis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Endometriosis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Endometriosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Endometriosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Endometriosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Endometriosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Endometriosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Endometriosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Endometriosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Endometriosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Endometriosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Endometriosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Endometriosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Hormonal Contraceptives
  • Progesterone Replacement Therapy
  • GnRHAnalogue
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Bayer
  • Abbott
  • Ferring
  • Xianju Pharma
  • AstraZeneca
  • Merck & Co
  • Takeda Pharmaceutical
  • Theramex
  • Livzon Pharmaceutical Group
  • Beijing Biote Pharmaceutical Co., ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Endometriosis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Endometriosis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Endometriosis Treatment Market Dynamics
  1. 2.1 Endometriosis Treatment Industry Trends
  2. 2.2 Endometriosis Treatment Industry Drivers
  3. 2.3 Endometriosis Treatment Industry Opportunities and Challenges
  4. 2.4 Endometriosis Treatment Industry Restraints
3 Endometriosis Treatment Market by Company
  1. 3.1 Global Endometriosis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Endometriosis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Endometriosis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Endometriosis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Endometriosis Treatment Company Product Type and Application
  6. 3.6 Global Endometriosis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Endometriosis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Endometriosis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Endometriosis Treatment Market by Type
  1. 4.1 Endometriosis Treatment Type Introduction
  2. 4.1.1 Hormonal Contraceptives
  3. 4.1.2 Progesterone Replacement Therapy
  4. 4.1.3 GnRHAnalogue
  5. 4.2 Global Endometriosis Treatment Sales Value by Type
  6. 4.2.1 Global Endometriosis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Endometriosis Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Endometriosis Treatment Sales Value Share by Type (2021-2032)
5 Endometriosis Treatment Market by Application
  1. 5.1 Endometriosis Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Endometriosis Treatment Sales Value by Application
  6. 5.2.1 Global Endometriosis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Endometriosis Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Endometriosis Treatment Sales Value Share by Application (2021-2032)
6 Endometriosis Treatment Regional Value Analysis
  1. 6.1 Global Endometriosis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Endometriosis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Endometriosis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Endometriosis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Endometriosis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Endometriosis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Endometriosis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Endometriosis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Endometriosis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Endometriosis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Endometriosis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Endometriosis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Endometriosis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Endometriosis Treatment Sales Value Share by Country, 2025 VS 2032
7 Endometriosis Treatment Country-level Value Analysis
  1. 7.1 Global Endometriosis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Endometriosis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Endometriosis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Endometriosis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Endometriosis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Endometriosis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Endometriosis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer
  2. 8.1.1 Bayer Company Information
  3. 8.1.2 Bayer Business Overview
  4. 8.1.3 Bayer Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Endometriosis Treatment Product Portfolio
  6. 8.1.5 Bayer Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Endometriosis Treatment Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Ferring
  14. 8.3.1 Ferring Company Information
  15. 8.3.2 Ferring Business Overview
  16. 8.3.3 Ferring Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ferring Endometriosis Treatment Product Portfolio
  18. 8.3.5 Ferring Recent Developments
  19. 8.4 Xianju Pharma
  20. 8.4.1 Xianju Pharma Company Information
  21. 8.4.2 Xianju Pharma Business Overview
  22. 8.4.3 Xianju Pharma Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Xianju Pharma Endometriosis Treatment Product Portfolio
  24. 8.4.5 Xianju Pharma Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Endometriosis Treatment Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Merck & Co
  32. 8.6.1 Merck & Co Company Information
  33. 8.6.2 Merck & Co Business Overview
  34. 8.6.3 Merck & Co Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co Endometriosis Treatment Product Portfolio
  36. 8.6.5 Merck & Co Recent Developments
  37. 8.7 Takeda Pharmaceutical
  38. 8.7.1 Takeda Pharmaceutical Company Information
  39. 8.7.2 Takeda Pharmaceutical Business Overview
  40. 8.7.3 Takeda Pharmaceutical Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Pharmaceutical Endometriosis Treatment Product Portfolio
  42. 8.7.5 Takeda Pharmaceutical Recent Developments
  43. 8.8 Theramex
  44. 8.8.1 Theramex Company Information
  45. 8.8.2 Theramex Business Overview
  46. 8.8.3 Theramex Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Theramex Endometriosis Treatment Product Portfolio
  48. 8.8.5 Theramex Recent Developments
  49. 8.9 Livzon Pharmaceutical Group
  50. 8.9.1 Livzon Pharmaceutical Group Company Information
  51. 8.9.2 Livzon Pharmaceutical Group Business Overview
  52. 8.9.3 Livzon Pharmaceutical Group Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Livzon Pharmaceutical Group Endometriosis Treatment Product Portfolio
  54. 8.9.5 Livzon Pharmaceutical Group Recent Developments
  55. 8.10 Beijing Biote Pharmaceutical Co., ltd
  56. 8.10.1 Beijing Biote Pharmaceutical Co., ltd Company Information
  57. 8.10.2 Beijing Biote Pharmaceutical Co., ltd Business Overview
  58. 8.10.3 Beijing Biote Pharmaceutical Co., ltd Endometriosis Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Biote Pharmaceutical Co., ltd Endometriosis Treatment Product Portfolio
  60. 8.10.5 Beijing Biote Pharmaceutical Co., ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst